Actuate Therapeutics (ACTU) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist

8.130
-0.550-6.34%

Close Nov 29 13:00 ET

158.79MMarket Cap-5579P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Actuate Therapeutics to Be Added to Russell 2000® Index
ReutersNov 26 08:02 ET
Actuate Therapeutics to Be Added to Russell 2000 Index
GlobeNewswireNov 26 08:00 ET
Top Premarket Decliners
MT NewswiresNov 25 08:10 ET
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment
WSJNov 12 08:34 ET
Express News | Actuate Therapeutics Inc - Topline Phase 1 Data for Elraglusib Expected in 2H 2025
ReutersNov 12 08:01 ET
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
GlobeNewswireOct 29 18:39 ET

Comments

Teddy123

Oct 29 22:55

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

$Actuate Therapeutics (ACTU.US)$
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted b...